
Hany Lashen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5850675/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications. Efficacy and Mechanism Evaluation, 2016, 3, 1-800.	0.9	5
2	Socioeconomic conditions across life related to multiple measures of the endocrine system in older adults: Longitudinal findings from a British birth cohort study. Social Science and Medicine, 2015, 147, 190-199.	1.8	19
3	Changes in testosterone related to body composition in late midlife: Findings from the 1946 British birth cohort study. Obesity, 2015, 23, 1486-1492.	1.5	28
4	Prenatal Exposure to Perfluoroalkyl Acids and Serum Testosterone Concentrations at 15 Years of Age in Female ALSPAC Study Participants. Environmental Health Perspectives, 2015, 123, 1325-1330.	2.8	46
5	Changes in insulinâ€like growth factorâ€l and â€ll associated with fat but not lean mass in early old age. Obesity, 2015, 23, 692-698.	1.5	22
6	Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 778-786.	5.5	206
7	Impact of gestational weight gain on fetal growth in obese normoglycemic mothers: a comparative study. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 771-777.	1.3	7
8	Fetal growth in relation to maternal and fetal <scp>IGF</scp> â€exes: a systematic review and metaâ€enalysis. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 997-1006.	1.3	23
9	Peripubertal changes in circulating antimüllerian hormone levels in girls. Fertility and Sterility, 2013, 99, 2071-2075.	0.5	37
10	Prenatal Exposures and Anti-Müllerian Hormone in Female Adolescents. American Journal of Epidemiology, 2013, 178, 1414-1423.	1.6	23
11	Bowel dysfunction after total abdominal hysterectomy for benign conditions. European Journal of Gastroenterology and Hepatology, 2013, 25, 1.	0.8	3
12	Anti-Müllerian Hormone Is Not Associated with Cardiometabolic Risk Factors in Adolescent Females. PLoS ONE, 2013, 8, e64510.	1.1	27
13	Urodynamic Outcomes After Hysterectomy for Benign Conditions. Obstetrical and Gynecological Survey, 2012, 67, 45-54.	0.2	19
14	Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. Fertility and Sterility, 2011, 95, 2429.e5-2429.e7.	0.5	7
15	Do South Asian women with PCOS have poorer health-related quality of life than Caucasian women with PCOS? A comparative cross-sectional study. Health and Quality of Life Outcomes, 2010, 8, 149.	1.0	28
16	Tibolone as a hormone replacement in women with endometriosis after bilateral oophorectomy. International Journal of Gynecology and Obstetrics, 2010, 111, 183-183.	1.0	0
17	Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate. Fertility and Sterility, 2009, 91, 1135-1140.	0.5	11
18	Empty follicle syndrome: the reality of a controversial syndrome, a systematic review. Fertility and Sterility, 2008, 90, 691-698.	0.5	86

HANY LASHEN

#	Article	IF	CITATIONS
19	Dynamics of pituitary down-regulation and ovarian response to controlled stimulation in in vitro fertilization cycles. Fertility and Sterility, 2007, 87, 433-435.	0.5	1
20	Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertility and Sterility, 2006, 86, 1515-1517.	0.5	50
21	Effect of gonadotropin-releasing hormone agonist and antagonist on steroidogenesis of low responders undergoingin vitrofertilization. Gynecological Endocrinology, 2006, 22, 57-62.	0.7	10
22	Endometriosis affects sperm–endosalpingeal interactions. Human Reproduction, 2005, 20, 448-451.	0.4	37
23	Agonist "flare-up―versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertility and Sterility, 2005, 83, 331-335.	0.5	59
24	Modern embryo transfer catheters and pregnancy outcome: a prospective randomized trial. Fertility and Sterility, 2005, 84, 996-1000.	0.5	16
25	The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. Human Reproduction, 2004, 19, 371-377.	0.4	115
26	Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. Human Reproduction, 2004, 19, 1644-1646.	0.4	459
27	Can formal education and training improve the outcome of instrumental delivery?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 113, 139-144.	0.5	51
28	The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstetricia Et Gynecologica Scandinavica, 2003, 82, 1112-1119.	1.3	41
29	Successful treatment of empty follicle syndrome by triggering endogenous LH surge using GnRH agonist in an antagonist down-regulated IVF cycle. Human Reproduction, 2003, 18, 2079-2081.	0.4	38
30	Trends in the management of the breech presentation at term; experience in a District General hospital over a 10-year period. Acta Obstetricia Et Gynecologica Scandinavica, 2002, 81, 1116-1122.	1.3	12
31	Management of poor responders in IVF. Human Reproduction, 1999, 14, 1919-1919.	0.4	9
32	Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 107-112.	1.1	108
33	Superovulation with a high gonadotropin dose for in vitro fertilization: Is it effective?. Journal of Assisted Reproduction and Genetics, 1998, 15, 438-443.	1.2	24